Cryoport reported Q3 2025 revenue of $44.2 million, up 15% year‑over‑year, surpassing consensus estimates of $41.36 million. The increase was driven by a 36% jump in commercial cell and gene therapy revenue to $8.3 million, reflecting robust demand in the regenerative‑medicine market.
Earnings per share fell to a loss of $0.18, beating the consensus loss of $0.21. The improvement stemmed from disciplined cost management and a favorable mix shift toward higher‑margin services, offsetting a modest rise in operating expenses.
Gross margin expanded to 48.2% from 45.5% in Q3 2024, driven by higher pricing power in the life‑sciences services segment and improved operational leverage as volume grew.
The company posted a net loss of $6.9 million, a narrowing from the $12.3 million loss in Q3 2024, reflecting reduced one‑time charges and better cost control.
Cryoport raised its full‑year 2025 revenue guidance to $170–$174 million, up from $165–$172 million, citing continued momentum in the cell‑and‑gene therapy market and new contract wins. The guidance lift signals management confidence in sustained demand and margin improvement.
Share repurchases totaled 483,397 shares at an average price of $7.73, underscoring the company’s commitment to returning value to shareholders.
With $421.3 million in cash, cash equivalents, and short‑term investments, Cryoport maintains a strong balance sheet that supports ongoing investments in its global supply‑chain platform and strategic initiatives.
CEO Jerrell Shelton highlighted the company’s “visible pathway to profitability” and praised the “double‑digit growth” in commercial services, noting that the company remains the only pure‑play end‑to‑end temperature‑controlled supply‑chain provider for the largest portfolio of cell and gene therapies.
Investors responded positively to the results, citing the earnings beat, revenue growth, and guidance upgrade as evidence of the company’s continued execution and market leadership.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.